The effect of cost construction based on either DRG or ICD-9 codes or risk group stratification on the resulting cost-effectiveness ratios

PharmacoEconomics

Volumn 22, Issue 18, 2004, Pages 1209-1216

  Chumney, Elinor C G ^a   Biddle, Andrea K ^b   Simpson, Kit N ^a   Weinberger, Morris ^b   Magruder, Kathryn M ^a   Zelman, William N ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COST EFFECTIVENESS ANALYSIS; DIAGNOSIS RELATED GROUP; DISEASE CLASSIFICATION; DRUG COST; HEALTH CARE POLICY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL COST; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL CLASSIFICATION OF DISEASES; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; COST-BENEFIT ANALYSIS; DIAGNOSIS-RELATED GROUPS; HIV INFECTIONS; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; RISK ASSESSMENT;

EID: 11344264117     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200422180-00005     Document Type: Article

References (31)

1. Gold M, Siegel J, Russell L, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
2. Simpson KN. Modeling with clinical trial data: moving from the data researchers have to the data decision makers need. Drug Int J 1995; 29: 1431-40
3. Swindle RW, Beattie MC, Barnett PG. The quality of cost data: a caution from the Department of Veterans Affairs experience. Med Care 1996; 34 Suppl. 3: MS83-90
4. Swindle RW, Lukas CV, Barnett PG, et al. Cost analysis in the Department of Veterans Affairs: consensus and future directions. Med Care 1999; 37 Suppl. 4: AS3-8
5. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada 1st ed. Ottawa: Canadian Coordinating Office for Health Technology Assessment, 1994
6. Luce BR, Elixhauser A. Estimating costs in the economic evaluation of medical technologies. Int J Technol Assess Health Care 1990; 6: 57-75
7. Luce B, Simpson K. Methods of cost-effectiveness analysis: areas of consensus and debate. Washington, (DC): Battelle Medical Technology Assessment and Policy (MEDTAP) Research Center, 1993
8. Luce B, Simpson K. Methods of cost-effectiveness analysis: areas of consensus and debate. Clin Ther 1995; 17: 109-25
9. George B, Harris A, Mitchell A. Cost effectiveness analysis and the consistency of decision making: evidence from pharmaceutical reimbursement in Australia 1991-96. Melbourne, Australia: Centre for Health Program Evaluation, 1999. Working paper 89
10. Epstein AM. Evaluating the cost-effectiveness of pharmacologic therapy: where we've been and where we're going. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 10 Suppl. 4: 1-5
11. Sullivan SD, Liljas B, Buxton M, et al. Design and analytic considerations in determining the cost-effectiveness of early intervention in asthma from a multinational clinical trial. Control Clin Trials 2001; 22: 420-37
12. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee. Commonwealth Department of Human Services and Health. Canberra: Australian Government Publishing Services, 1995
13. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 1992; 146: 473-81
14. Manning WG. Panel on cost-effectiveness in health and medicine recommendations: identifying costs. J Clin Psychiatry 1999; 60 Suppl. 3: 54-6
15. Wolff N, Helminiak TW, Tebes JC. Getting the cost right in cost-effectiveness analysis. Am J Psychiatry 1997; 154: 736-43
16. Copley-Merriman C, Lair TJ. Valuation of medical resource units collected in health economic studies. Clin Ther 1994; 16: 553-68
17. Shwartz M, Young D, Siegrist R. The ratio of cost to charges: how good a basis for estimating costs? Inquiry 1995; 32 (4): 476-81
18. Ashby J. The accuracy of cost measures derived from Medicare cost report data. Hosp Cost Manag Account 1992; 3: 1-8
19. Andrulis DP, Weslowski VB, Gage LS. The 1987 US hospital AIDS survey. JAMA 1989; 262 (6): 784-94
20. The DRG Handbook. Baltimore (MD): HCIA Inc. and Cleveland, Ohio: Ernst & Young, 1998
21. Mauskopf JA, Toison JM, Simpson KN, et al. The impact of zidovudine-based triple combination therapy on an AIDS drug assistance program. J Acquir Immune Defic Syndr 2000; 23: 302-13
22. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Pharmacoeconomics: identifying the issues. Advisory Panel Reports [online]. Available from URL: http://www.ispor.org/workpaper/adpanel [Accessed 2001 Nov 13]
23. Barnett PG. Estimating costs with a clinical cost function [online]. Available from URL: http://www.herc.research. med.va.gov/microCF.htm [Accessed 2001 Oct 15]
24. Ellis RP, Pope GC, Iezzoni LI, et al. Diagnosis-based risk adjustment for Medicare capitation payments. Health Care Financ Rev 1996; 17: 101-28
25. Turner BJ, Markson LE, McKee L, et al. The AIDS-defining diagnosis and subsequent complications: a survival-based severity index. J Acquir Immun Defic Syndr 1991; 4: 1059-71
26. Simpson KN, Voit EO, Goodman R, et al. Estimating the social and economic benefits of pharmaceutical innovations: modeling clinical trial results in HIV-disease. Res Hum Cap Dev 2001; 14: 175-1998
27. Mauskopf J, Lacey L, Kempel A, et al. The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates. Am J Manag Care 1998; 4 (7): 1004-12
28. Meynard JL, Guiget M, Rachline A, et al. Factors predicting response to antiretroviral regimens with a protease inhibitor in HIV-infected subjects. Presse Med 2001; 30 (1): 5-10
29. Biddle AK, Simpson KN. Modeling the cost-effectiveness of nevirapine triple combination therapy and dual combination therapy for the treatment of HIV/AIDS in the United Kingdom. J Med Econ 1999; 2: 85-105
30. Simpson KN, Hatziandreu EJ, Andersson F, et al. Cost effectiveness of antiretroviral treatment with zalcitabine plus zidovudine for AIDS patients with CD4+ counts less than 300u/l in 5 European countries. Pharmacoeconomics 1994; 6: 553-62
31. Biddle AK, Simpson KN. Modeling the use of triple combination therapy in five countries: nevirapine, zidovudine, and didanosine. Value Health 2000; 3: 186-201